PharmAust Limited
(ASX:PAA) has won an amendment to the current trial protocol of a cancer treatment for dogs.
The original protocol required a 28 day trial for affected dogs, often challenging for dog owners. The new protocol only requires the drug to be administered via Soft-Gel capsule for a period of 7 days.
The change came about after PharmAust could prove that its PPL-1 drug had an impact on key tumour markers and blood cells after 3 days in human patients.
PharmAust hopes to gain fast approval for the drug to take advantage of the $18 billion worth of pet care sales in the US.
PharmAust reported a net loss of $1.07 million for the first half of the 2015 financial year.
